First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients

Wassim Abida; Dean F Bajorin; Jonathan E Rosenberg

doi:10.1016/j.hoc.2014.10.005

First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients

Hematol Oncol Clin North Am. 2015 Apr;29(2):319-28, ix-x. doi: 10.1016/j.hoc.2014.10.005. Epub 2014 Dec 15.

Authors

Wassim Abida¹, Dean F Bajorin², Jonathan E Rosenberg²

Affiliations

¹ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: abidam@mskcc.org.
² Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

PMID: 25836937
DOI: 10.1016/j.hoc.2014.10.005

Abstract

Metastatic urothelial carcinoma is primarily a disease of the elderly, with a median overall survival of approximately 15 months. Cisplatin-based combination chemotherapy is standard first-line treatment for eligible patients, with carboplatin-based regimens used as an alternative for patients considered unfit to receive cisplatin. Prognostic models incorporating clinical risk factors have been validated, and molecular characteristics that predict for treatment response are under investigation. This review summarizes the current status of first-line treatment of metastatic urothelial carcinoma in platinum-eligible patients as well as prognostic and predictive models in this disease.

Keywords: Platinum chemotherapy; Prognostic factors; Urothelial carcinoma, metastatic.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Neoplasm Metastasis
Platinum / administration & dosage
Prognosis
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / mortality
Urinary Bladder Neoplasms / pathology*

Substances

Platinum